Brief: Shanghai Junshi Biosciences Says Drug Office In Hong Kong Accepted New Drug Application Of Toripalimab
24/04/2024 15:27
April 24 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* DRUG OFFICE IN HONG KONG ACCEPTED NEW DRUG APPLICATION OF
TORIPALIMAB
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab